Welcome to the UPF Digital Repository

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice

Show simple item record

dc.contributor.author Aso Pérez, Ester
dc.contributor.author Sánchez Pla, Alexandre
dc.contributor.author Vegas Lozano, Esteban
dc.contributor.author Maldonado, Rafael, 1961-
dc.contributor.author Ferrer, Isidre
dc.date.accessioned 2015-03-30T07:21:06Z
dc.date.available 2015-03-30T07:21:06Z
dc.date.issued 2015
dc.identifier.citation Aso E, Sánchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J Alzheimers Dis. 2015; 43(3): 977-91. DOI: 10.3233/JAD-141014
dc.identifier.issn 1387-2877
dc.identifier.uri http://hdl.handle.net/10230/23305
dc.description.abstract Several recent findings suggest that targeting the endogenous cannabinoid system can be considered as a potential therapeutic approach to treat Alzheimer's disease (AD). The present study supports this hypothesis demonstrating that delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids, which are the components of an already approved cannabis-based medicine, preserved memory in AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Moreover, THC + CBD reduced learning impairment in AβPP/PS1 mice. A significant decrease in soluble Aβ42 peptide levels and a change in plaques composition were also observed in THC + CBD-treated AβPP/PS1 mice, suggesting a cannabinoid-induced reduction in the harmful effect of the most toxic form of the Aβ peptide. Among the mechanisms related with these positive cognitive effects, the anti-inflammatory properties of cannabinoids may also play a relevant role. Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AβPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD. Moreover, other cannabinoid-induced effects were uncovered by a genome-wide gene expression study. Thus, we have identified the redox protein thioredoxin 2 and the signaling protein Wnt16 as significant substrates for the THC + CBD-induced effects in our AD model. In summary, the present findings show that the combination of THC and CBD exhibits a better therapeutic profile than each cannabis component alone and support the consideration of a cannabis-based medicine as potential therapy against AD.
dc.description.sponsorship This study was supported by grants from the Agrupació Mútua Foundation (XVII Award in the Elderly Field, to IF), Mutua Madrileña Foundation (IF), and BESAD-P project, CIBERNED, Instituto Carlos III (IF).
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher IOS Press
dc.rights © IOS Press. All rights reserved
dc.subject.other Cannabis
dc.subject.other Medicina
dc.subject.other Alzheimer, Malaltia d'
dc.title Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3233/JAD-141014
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking